←
ABK Biomedical Inc.43 posts
ABK Biomedical Inc. avatar

ABK Biomedical Inc.

@ABKBiomedical

We are a leading innovator in the clinical development of glass microspheres solutions for the treatment of hypervascular tumors

◷ Joined September 2022▧ 30 Photos and videos
ABK Biomedical Inc. avatar
ABK Biomedical Inc.@ABKBiomedical·Oct 26

Thank you to the Interventional Oncology (IO) professionals who bring precision and compassion to patients every day. ABK Biomedical is proud to stand with you this #IOAWARENESSWEEK as we continue to build advanced therapies to improve patient outcomes together!

Post attachment
ABK Biomedical Inc. avatar
ABK Biomedical Inc.@ABKBiomedical·Mar 31

ABK Biosciences formalized a long-term partnership with the University of Missouri Research Reactor (MURR) — naming MURR as the primary irradiation partner for Eye90 microspheres®, our Y-90 radioembolization therapy for liver cancer. 🔗 Read more: prnewswire.com/news-releases…

ABK Biomedical Inc. avatar
ABK Biomedical Inc.@ABKBiomedical·Feb 24

🚨 Milestone Alert: ABK Biomedical has completed enrollment in ROUTE90 - the largest prospective FDA IDE trial for Y90 treatment of liver cancer (HCC). 120 patients. One big step closer to FDA approval of Eye90 microspheres. #HCC #LiverCancer #Oncology prnewswire.com/news-releases…

ABK Biomedical Inc. avatar
ABK Biomedical Inc.@ABKBiomedical·Feb 12

We are hiring for a Manufacturing Process Development Engineer. Does this sound like you or someone you know? Visit or website or click the link for the job description and further details. linkedin.com/jobs/view/43712…

ABK Biomedical Inc. avatar
ABK Biomedical Inc.@ABKBiomedical·21 Nov 2025

ABK is proud to share that the first Canadian patient has been successfully treated with Eye90 microspheres® as part of the Route90 clinical trial. A sincere thank you to Dr. Rajvot Dhatt, his outstanding team at Vancouver General Hospital, and all other study contributors.

Post attachment
ABK Biomedical Inc. avatar
ABK Biomedical Inc.@ABKBiomedical·14 Oct 2025

ABK Biomedical Raises US$35M in Series D Financing Grateful for J.P. Morgan Life Sciences Private Capital leading this round, along with our outstanding syndicate of existing investors! prnewswire.com/news-releases…

ABK Biomedical Inc. avatar
ABK Biomedical Inc.@ABKBiomedical·18 Sep 2025

The latest article on Y-90 in Radiation Oncology highlights the increasing body of evidence supporting its use in treating patients w/liver cancer. ABK’s anticipated Route90 study results should contribute valuable L1 data to this expanding evidence base. ro-journal.biomedcentral.com…

ABK Biomedical Inc. avatar
ABK Biomedical Inc.@ABKBiomedical·8 Sep 2025

As published in a recent JVIR article, Y90 post-procedure PET/SPECT imaging shown to inform better pt. follow-up. Looking forward to seeing how Eye90 microspheres Precision Dosimetry® compares to Y90 PET/SPECT when ABK’s Route90 clinical trial reads out. bit.ly/4g9iNo6

ABK Biomedical Inc. avatar
ABK Biomedical Inc.@ABKBiomedical·10 Jun 2024

ABK Biomedical Inc. team focused on our future in China. Special thanks to Eight Roads, Medtronic China, Lei Shi, Delphine Qui, Alex Gu, Michael Wang, Tony Xu. Great strategic assistance from Dr. Dave Liu, Dr. Zhong Qian, Prof Gao-Jun Teng.

Post attachmentPost attachmentPost attachmentPost attachment